This research grant was approved by Komen’s national board of directors for FY2014 Research Programs funding. This grant will be funded upon the execution of grant agreements between Komen and the grantee institutions.

**Clinical trials for HER2+ breast cancer**

**Investigator(s):** Eric Winer, M.D.

**Lead Organization:** Dana-Farber Cancer Institute

**Grant Mechanism:** SAB Grants

**Grant ID:** SAB1500001

**Public Abstract:**

Dr. Eric Winer and colleagues will continue research that is focused on patients with HER2+ breast cancer. They are seeking to develop improved treatment strategies, particularly for patients with disease that is refractory to standard therapy and for patients with brain metastases. New treatment approaches will be tested in prospective clinical trials. In particular, we will test a novel approach using two antibodies (trastuzumab and pertuzumab) and a PI3kinase inhibitor in patients with refractory metastatic disease. We will also test an entirely novel anti-HER2 specific tyrosine kinase inhibitor in combination with trastuzumab in patients with HER2+ brain metastases.

If these studies, as well as others, are successful, this will lead to new potential treatment approaches for women with HER2+ metastatic disease. This work is of particularly importance because our available treatments, while highly effective, are still incapable of providing longterm disease control in a subset of patients. For those women who develop disease progression in spite of our currently available therapies, the outcome remains very poor. Ultimately, we hope that these approaches will also lead to improvements in the treatment of HER2+ early stage disease. Importantly, support from the Komen leadership grant will provide overall programmatic support that will allow the Dana-Farber team to pursue a broach of studies in the treatment of HER2+ disease.